Mammadova, D.
Vecko, J.
Hofmann, M.
Schüssler, S. C.
Deiters, L.
Canda, A.
Wieland, A. K.
Gollwitzer, S.
Hamer, H.
Trollmann, Regina http://orcid.org/0000-0001-6031-8537
Funding for this research was provided by:
Friedrich-Alexander-Universität Erlangen-Nürnberg
Article History
Received: 14 November 2022
Accepted: 25 October 2023
First Online: 9 November 2023
Declarations
:
: The study protocol was reviewed and approved by the local ethics committee of Friedrich-Alexander University of Erlangen-Nürnberg. The study was performed in accordance with the principles of Good Clinical Practice.
: Local ethics committee of the FAU Erlangen-Nürnberg.
: RT received honoraria and personal lectures fees from Eisai, Desitin, Roche, Sanofi, and Biogen. HH has served on the scientific advisory board of Angelini, Corlieve, Eisai, Neuroventis, GW/Jazz, Sandoz, UCB Pharma, UNEEG and Zogenix. He served on the speakers’ bureau of or received unrestricted grants from Ad-Tech, Alnylam, Angelini, Bracco, Desitin, Eisai, GW, Micromed, Nihon Kohden, Novartis, Pfizer, and UCB Pharma. SG, DM, JV, MH, SS, AC, and AKW report no conflict of interest.